2. Protein Tyrosine Kinase/RTK PI3K/Akt/mTOR MAPK/ERK Pathway Stem Cell/Wnt JAK/STAT Signaling Apoptosis Autophagy
  3. Src PI3K JNK STAT EGFR Apoptosis Autophagy
  4. Peruvoside

Peruvoside  (Synonyms: Encordin)

目录号: HY-108016
产品使用指南

摩尔计算器

Peruvoside 是一种有效的 Src，PI3K，JNK ，STAT，和 EGFR的抑制剂。Peruvoside 诱导细胞凋亡 (apoptosis) 和自噬 (autophagy)，在乳腺癌、肺癌、肝癌和白血病中具有广谱的抗肿瘤活性。Peruvoside 对正义 RNA 病毒具有广谱、强效的抗病毒活性。 Peruvoside 增加 Gefitinib (HY-50895) 耐药肿瘤细胞 (A549，PC9/gef和H1975) 的敏感性。。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Peruvoside Chemical Structure

Peruvoside Chemical Structure

CAS No. : 1182-87-2

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

Customer Review

Peruvoside 相关抗体

Top Publications Citing Use of Products

查看 Src 亚型特异性产品:

查看所有亚型
Lck

查看 PI3K 亚型特异性产品:

查看所有亚型
PI3Kα PI3Kβ PI3Kγ PI3Kδ PI3KC2α PI3KC2β PI3KC2γ Vps34 PI3K PI3KC3 p120γ

查看 JNK 亚型特异性产品:

查看所有亚型
JNK1 JNK2 JNK3 JNK

查看 STAT 亚型特异性产品:

查看所有亚型
STAT3 STAT5 STAT6 STAT1

查看 EGFR 亚型特异性产品:

查看所有亚型
EGFR/ErbB1/HER1 ErbB2/HER2 ErbB3/HER3 ErbB4/HER4

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Peruvoside is a potent inhibitor of Src, PI3K, JNK, STAT, and EGFR. Peruvoside induces apoptosis and autophagy and possesses a broad spectrum of anticancer activity in breast, lung, liver cancers and leukemia. Peruvoside is a broad-spectrum and potent antiviral activity against positive-sense RNA viruses. Peruvoside sensitizes Gefitinib (HY-50895)-resistant tumour cells (A549, PC9/gef and H1975) to Gefitinib[1][2][3][4].

体外研究
(In Vitro)

Peruvoside (50-5000 nM，24 小时) 抑制了 PC9，PC9/gef，H3255，和 H1975 细胞系的活力和增殖[1]。
Peruvoside (0.005-0.5 μM, 72 小时) 与 Gefitinib (0.01~0.5 μM) 联用时，增强了 A549， PC9/gef 和 H1975 细胞对 Gefitinib 的敏感程度[1]。
Peruvoside (0-100 μM，24 小时) 诱导 MCF-7，HpG2 和 A549 细胞的周期停滞和凋亡[2。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Peruvoside 相关抗体:

Cell Proliferation Assay[1]

Cell Line: PC9, PC9/gef, H3255, and H1975 cell lines
Concentration: 0, 0.01, 0.05, 0.1, 0.5, 1 μM
Incubation Time: 24, 48, 72, 96 h.
Result: Inhibited the viabilities of TKI-sensitive and TKI-resistant cell lines at all tested time points.
Inhibited the EGFR-mutant lung cancer cell viability and proliferation with 24 h IC50s of 48 nM, 74 nM, 67 nM, 143 nM, 277 nM and 428 nM for A549, PC9, PC9/gef, H3255, H1975 and BEAS-2B cells, respectively.
Significantly inhibited the proliferation of A549 (48, 72, and 96 h) and H3255 (24, 48, 72, and 96 h) lungcancer cells.

Cell Viability Assay[1]

Cell Line: A549, PC9/gef and H1975 cell lines
Concentration: 0.005, 0.0075, 0.01, 0.025, 0.05, 0.5 μM (in combination with 0.01, 0.05, 0.1, 0.25, 0.5 μM Gefitinib)
Incubation Time: 72 h.
Result: Had synergistic effects on A549 cells at the combination of 0.005, 0.075, or 0.01 μM and a low dose of gefitinib (0.01 or 0.05 μM).
Increased the sensitivity of PC9/gef and H1975 cells to Gefitinib at 0.025 or 0.05 μM.

Apoptosis Analysis[2]

Cell Line: MCF-7, A549 and HepG2 cell lines
Concentration: 0-100 μM
Incubation Time: 24 h
Result: Induced cell cycle arrest and apoptosis with lethal concentrations of IC50 for (MCF-7 - 100 nM), (A549 – 100 nM) and (HepG2 - 100 nM), respec-tively.
Arrested cell cycle at G0/G1 in MCF-7, A549 and HepG2 cells.
Significantly decreased the transcription of Chk1, Chk2, CDK6 and Cyclin D1 cell cycle genes in MCF-7, A549, and HepG2 cells.
体内研究
(In Vivo)

Peruvoside (0.1 mg/kg，腹腔注射；一天一次，连续 28 天) 抑制肺癌小鼠模型的肿瘤生长[1]。
Peruvoside (0.59 mg/kg，腹腔注射；一天一次，连续 7 天) 降低了 EV-A71 感染小鼠模型的死亡率[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Lung cancer mouse model[1]
Dosage: 0.1 mg/kg
Administration: Intraperitoneal injection (i.p.); Once daily for 28 days
Result: Reduced the tumour size to 129.9 mm3, which was significantly smaller than the control group (348 mm3).
Significantly decreased levels of phosphorylated Src Y419 in tumour tissues compared with control tissues.
Animal Model: EV-A71-infected mice model[4]
Dosage: 0.59 mg/kg
Administration: Intraperitoneal injection (i.p.); Once daily for 7 days
Result: Substantially reduced clinical scores based on physical symptoms of body weight, activity,breathing, movement, and dehydration.
Showed about 6 log reduction in viral titre with 99.9% efficacy in inhibiting virus.
分子量

548.66

Formula

C30H44O9
CAS 号
结构分类
初始来源
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
参考文献

Peruvoside 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Peruvoside1182-87-2EncordinSrcPI3KJNKSTATEGFRApoptosisAutophagyPhosphoinositide 3-kinasec-Jun N-terminal kinaseEpidermal growth factor receptorErbB-1HER1non-small-cell lung carcinomalung cancerA549PC9/gefH1975GefitinibNSCLCleukemiaPositive-sense RNA virusesInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
Peruvoside
目录号：
HY-108016
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z